(NASDAQ: NRIX) Nurix Therapeutics's forecast annual revenue growth rate of 53.55% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 34.63%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.72%.
Nurix Therapeutics's revenue in 2026 is $36,766,000.On average, 18 Wall Street analysts forecast NRIX's revenue for 2026 to be $6,141,073,528, with the lowest NRIX revenue forecast at $3,396,982,048, and the highest NRIX revenue forecast at $10,166,453,667. On average, 17 Wall Street analysts forecast NRIX's revenue for 2027 to be $10,923,022,136, with the lowest NRIX revenue forecast at $3,590,223,542, and the highest NRIX revenue forecast at $25,455,571,206.
In 2028, NRIX is forecast to generate $20,182,423,893 in revenue, with the lowest revenue forecast at $3,962,488,439 and the highest revenue forecast at $34,330,980,736.